| Kyla R Aschenbeck, MD | |
|
5717 Balcones Dr, Austin, TX 78731-4203 | |
| (512) 314-1613 | |
| (512) 314-1661 |
| Full Name | Kyla R Aschenbeck |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 9 Years |
| Location | 5717 Balcones Dr, Austin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982091674 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 70818 (Wisconsin) | Secondary |
| 207W00000X | Ophthalmology | S6566 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texan Eye, Pa | 2466440458 | 16 |
News Archive
Gene therapies are being approved for use in Canada, but could strain healthcare budgets and exacerbate existing treatment inequities across the country.
Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.
pSivida Corp., a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported the submission of its response to the second Complete Response Letter from the U.S. Food and Drug Administration with respect to ILUVIEN for chronic diabetic macular edema.
A research involving scientists from the University of Alicante and the United States notes that the accumulation of a protein known as alpha-synuclein in the retina is a key Parkinson's biomarker that could help detect the degree of severity of the disease.
Socioeconomic factors such as a lower level of education and lack of health insurance may impact individuals' knowledge of the type of skin cancer with which they are diagnosed. As a result, these individuals may have a poor sense of the measures they need to take to reduce the risk of future skin cancers.
› Verified 4 days ago
| Entity Name | Texan Eye, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205813961 PECOS PAC ID: 2466440458 Enrollment ID: O20040506000650 |
News Archive
Gene therapies are being approved for use in Canada, but could strain healthcare budgets and exacerbate existing treatment inequities across the country.
Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.
pSivida Corp., a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported the submission of its response to the second Complete Response Letter from the U.S. Food and Drug Administration with respect to ILUVIEN for chronic diabetic macular edema.
A research involving scientists from the University of Alicante and the United States notes that the accumulation of a protein known as alpha-synuclein in the retina is a key Parkinson's biomarker that could help detect the degree of severity of the disease.
Socioeconomic factors such as a lower level of education and lack of health insurance may impact individuals' knowledge of the type of skin cancer with which they are diagnosed. As a result, these individuals may have a poor sense of the measures they need to take to reduce the risk of future skin cancers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyla R Aschenbeck, MD 5717 Balcones Dr, Austin, TX 78731-4203 Ph: (512) 314-1613 | Kyla R Aschenbeck, MD 5717 Balcones Dr, Austin, TX 78731-4203 Ph: (512) 314-1613 |
News Archive
Gene therapies are being approved for use in Canada, but could strain healthcare budgets and exacerbate existing treatment inequities across the country.
Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.
pSivida Corp., a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported the submission of its response to the second Complete Response Letter from the U.S. Food and Drug Administration with respect to ILUVIEN for chronic diabetic macular edema.
A research involving scientists from the University of Alicante and the United States notes that the accumulation of a protein known as alpha-synuclein in the retina is a key Parkinson's biomarker that could help detect the degree of severity of the disease.
Socioeconomic factors such as a lower level of education and lack of health insurance may impact individuals' knowledge of the type of skin cancer with which they are diagnosed. As a result, these individuals may have a poor sense of the measures they need to take to reduce the risk of future skin cancers.
› Verified 4 days ago
Dr. Kristen Michelle Hawthorne, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Saradha Chexal, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy Ste 460, Austin, TX 78705 Phone: 512-454-5851 | |
Dr. John David Fisher, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2901 Montopolis Dr, Austin, TX 78741 Phone: 512-389-6571 Fax: 512-389-6511 | |
Dr. Clio Armitage Harper Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 W 38th St, Suite 200, Austin, TX 78705 Phone: 512-451-0103 Fax: 512-451-2741 | |
Dr. Nadja Ivette Torres, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Fuad Makkouk, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9707 Anderson Mill Rd Ste 230, Austin, TX 78750 Phone: 512-693-9363 | |
Irina Volosko, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3410 Far West Blvd Ste 140, Austin, TX 78731 Phone: 512-427-1107 Fax: 512-427-1207 |